外周血HBV_cccDNA检测在乙型肝炎患者抗病毒治疗中的应用  

Application of peripheral blood HBV cccDNA detection in antiviral treatment of patients with Hepatitis B

作　　者：许锴[1] 翁雪健[1] 卢洁[1] 张德亭[1] 童郁[1] 李君[1] 

机构地区：[1]浙江省温州市第三人民医院,浙江温州325000

出　　处：《中国卫生检验杂志》2012年第6期1370-1371,1374,共3页Chinese Journal of Health Laboratory Technology

摘　　要：目的:研究外周血cccDNA在乙肝患者抗病毒治疗中的作用。方法:在34例乙型肝炎患者抗病毒治疗前、6个月和12个月采集外周血,分别检测血浆ALT、AST、cccDNA、HBV-DNA和单个核细胞的cccD-NA,进行统计学分析。结果:ALT、AST水平在抗病毒治疗前与治疗6个月、12个月均有差别(P<0.01),但治疗12个月与6个月无差别(P分别为0.36、0.28);血浆cccDNA与HBV-DNA治疗前、治疗6个月与12个月三组间均有差别(P<0.01);按治疗前血浆cccDNA阴、阳性分组,治疗6个月后HBV-DNA转阴率有差别(P=0.048<0.05),治疗12个月后HBV-DNA转阴率无差别(P=0.667)。结论:外周血血浆cccD-NA检测对抗病毒治疗有一定预测意义。外周血单个核细胞cccDNA的检测对于肝移植患者乙肝的复发提供了理论依据。Objective：To study peripheral blood cccDNA use in antiviral therapy for hepatitis B sufferers.Methods：Peripheral blood samples from 34 hepatitis B patients were collected before treatment,6 months and 12 months after treatment,then plasma ALT,AST,cccDNA,HBV-DNA and mononuclear cccDNA were statistically analyzed.Results：Levels of ALT and AST before antiviral treatment had differences with those of 6 months and 12 months after treatment（P0.01）,but no difference was found between 12 months and 6 months after treatment（P values were 0.36 and 0.28 respectively）.Plasma cccDNA and HBV-DNA had differences among levels before antiviral treatment,6 months and 12 months after treatment（P0.01）.According to the plasma cccDNA negative and positive before treatment,the samples were grouped.HBV-DNA negative-converting rate changed significantly after treatment for 6 months（P=0.0480.05）,while HBV-DNA negative-converting rate changed little after treatment for 12 months（P=0.067）.Conclusion：Peripheral blood cccDNA detection had certain significance in prediction of antiviral therapy,and detection of mononuclear cccDNA in peripheral blood can provide theoretical basis for recurrence of hepatitis B in liver transplant patients.

关 键 词：乙型肝炎 HBV-DNA 共价闭合环状DNA 抗病毒治疗 

分 类 号：R512.62[医药卫生—内科学]